AQR Capital Management LLC Buys 28,027 Shares of Twist Bioscience Co. (NASDAQ:TWST)

AQR Capital Management LLC boosted its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 83.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 61,428 shares of the company’s stock after buying an additional 28,027 shares during the quarter. AQR Capital Management LLC’s holdings in Twist Bioscience were worth $3,027,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Baillie Gifford & Co. grew its stake in Twist Bioscience by 12.1% during the 1st quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company’s stock valued at $42,116,000 after purchasing an additional 132,770 shares during the last quarter. Point72 Asset Management L.P. grew its stake in Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after purchasing an additional 613,057 shares during the last quarter. Fred Alger Management LLC grew its stake in Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after purchasing an additional 575,080 shares during the last quarter. Ensign Peak Advisors Inc boosted its stake in shares of Twist Bioscience by 74.6% in the second quarter. Ensign Peak Advisors Inc now owns 331,373 shares of the company’s stock worth $16,330,000 after buying an additional 141,557 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in shares of Twist Bioscience by 40.8% in the second quarter. Sei Investments Co. now owns 314,658 shares of the company’s stock worth $15,507,000 after buying an additional 91,103 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Barclays lowered their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. JPMorgan Chase & Co. increased their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. TD Cowen increased their price target on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Robert W. Baird increased their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Finally, Evercore ISI increased their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $51.63.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $42.15 on Tuesday. The stock has a market cap of $2.45 billion, a PE ratio of -12.54 and a beta of 1.77. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $60.90. The stock has a 50 day moving average price of $44.63 and a 200 day moving average price of $43.80.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The business had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company’s revenue was up 27.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.01) earnings per share. As a group, analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Patrick John Finn sold 2,207 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total value of $124,960.34. Following the completion of the transaction, the chief operating officer now owns 171,212 shares of the company’s stock, valued at approximately $9,694,023.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Twist Bioscience news, CEO Emily M. Leproust sold 5,139 shares of the stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $205,200.27. Following the sale, the chief executive officer now directly owns 499,593 shares of the company’s stock, valued at approximately $19,948,748.49. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO Patrick John Finn sold 2,207 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $56.62, for a total transaction of $124,960.34. Following the completion of the transaction, the chief operating officer now directly owns 171,212 shares in the company, valued at $9,694,023.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,390 shares of company stock valued at $1,793,567. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.